Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease

키워드

참고문헌 (54)

1. Holtzman DM, "Alzheimer’s disease : the challenge of the second century", Sci Transl Med, 3, pp.77~ (2011)
2. Levey A, "Mild cognitive impairment : an opportunity to identify patients at high risk for progression to Alzheimer’s disease", Clin Ther, 28, pp.991~1001 (2006)
3. Sullivan PF, "Evaluating the comparability of gene expression in blood and brain", Am J Med Genet B Neuropsychiatr Genet, 141B, pp.261~268 (2006)
4. Cardinali DP, "The use of melatonin in Alzheimer’s disease", Neuro Endocrinol Lett, 23(Suppl 1), pp.20~23 (2002)
5. Altun A, "Melatonin : therapeutic and clinical utilization", Int J Clin Pract, 61, pp.835~845 (2007)
6. Hardeland R, "Antioxidative protection by melatonin : multiplicity of mechanisms from radical detoxification to radical avoidance", Endocrine, 27, pp.119~130 (2005)
7. Ishio S, "HydroxyindoleO-methyltransferase is another target for L-glutamate-evoked inhibition of melatonin synthesis in rat pinealocytes", Brain Res, 850, pp.73~78 (1999)
8. Yamada H, "Metabotropic glutamate receptors negatively regulate melatonin synthesis in rat pinealocytes", J Neurosci, 18, pp.2056~2062 (1998)
9. Villela D, "Modulation of pineal melatonin synthesis by glutamate involves paracrine interactions between pinealocytes and astrocytes through NF-B activation", Biomed Res Int, 2013, pp.618432~ (2013)
10. Bavithra S, "Effect of melatonin on glutamate : BDNF signaling in the cerebral cortex of polychlorinated biphenyls(PCBs)-exposed adult male rats", Neurochem Res, 40, pp.1858~1869 (2015)
11. Juan WS, "Melatonin improves neuroplasticity by upregulating the growth-associated protein-43(GAP-43)and NMDAR postsynaptic density-95(PSD-95)proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebral ischemia even during a long-term recovery period", J Pineal Res, 56, pp.213~223 (2014)
12. Zhou JN, "Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels", J Pineal Res, 35, pp.125~130 (2003)
13. Srinivasan V, "Melatonin in Alzheimer’s disease and other neurodegenerative disorders", Behav Brain Funct, 2, pp.15~ (2006)
14. Liu RY, "Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4", 4 genotype, 1999, pp.84, 323~327
15. Uchida K, "Daily rhythm of serum melatonin in patients with dementia of the degenerate type", Brain Res, 717, pp.154~159 (1996)
16. Cardinali DP, "Clinical aspects of melatonin intervention in Alzheimer’s disease progression", Curr Neuropharmacol, 8, pp.218~227 (2010)
17. Cardinali DP, "The use of chronobiotics in the resynchronization of the sleep", wake cycle. Therapeutical application in the early phases of Alzheimer’s disease, 2011, pp.5, 80~90
18. McCleery J, "Pharmacotherapies for sleep disturbances in dementia", Cochrane Database Syst Rev, 11, pp.CD009178~ (2016)
19. Fourtillan JB, "Melatonin secretion occurs at a constant rate in both young and older men and women", Am J Physiol Endocrinol Metab, 280, pp.E11~ (2001)
20. Lu PH, "Donepezil delays progression to AD in MCI subjects with depressive symptoms", Neurology, 72, pp.2115~2121 (2009)
21. McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
22. Morris JC, "The Clinical Dementia Rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
23. Folstein MF, "“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
24. Crum RM, "Populationbased norms for the Mini-Mental State Examination by age and educational level", JAMA, 269, pp.2386~2391 (1993)
25. Tombaugh TN, "The mini-mental state examination : a comprehensive review", J Am Geriatr Soc, 40, pp.922~935 (1992)
26. Lim WS, "Utility of the clinical dementia rating in Asian populations", Clin Med Res, 5, pp.61~70 (2007)
27. Rockwood K, "Interrater reliability of the Clinical Dementia Rating in a multicenter trial", J Am Geriatr Soc, 48, pp.558~559 (2000)
28. Hughes CP, "A new clinical scale for the staging of dementia", Br J Psychiatry, 140, pp.566~572 (1982)
29. Sack RL, "Human melatonin production decreases with age", J Pineal Res, 3, pp.379~388 (1986)
30. Grad BR, "The role of melatonin and serotonin in aging : update", Psychoneuroendocrinology, 18, pp.283~295 (1993)
31. Srinivasan V, "Melatonin and its agonist ramelteon in Alzheimer’s disease : possible therapeutic value", Int J Alzheimers Dis, 2011, pp.741974~ (2010)
32. Wu YH, "The human pineal gland and melatonin in aging and Alzheimer’s disease", J Pineal Res, 38, pp.145~152 (2005)
33. Hardeland R, "Melatonin", Int J Biochem Cell Biol, 38, pp.313~316 (2006)
34. Cagnacci A, "Melatonin in relation to physiology in adult humans", J Pineal Res, 21, pp.200~213 (1996)
35. Ohashi Y, "Differential pattern of the circadian rhythm of serum melatonin in young and elderly healthy subjects", Biol Signals, 6, pp.301~306 (1997)
36. Scholtens RM, "Physiological melatonin levels in healthy older people : a systematic review", J Psychosom Res, 86, pp.20~27 (2016)
37. Terzieva DD, "Melatonin reference limits at 3 : 00 AM and 8 : 00 AM in healthy adults", Clin Lab, 55, pp.359~361 (2009)
38. Ji LD, "Association of disease-predisposition polymorphisms of the melatonin receptors and sunshine duration in the global human populations", J Pineal Res, 48, pp.133~141 (2010)
39. Obayashi K, "Positive effect of daylight exposure on nocturnal urinary melatonin excretion in the elderly : a cross-sectional analysis of the HEIJO-KYO study", J Clin Endocrinol Metab, 97, pp.4166~4173 (2012)
40. Kasper S, "Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder : a randomized, double-blind comparison with sertraline", J Clin Psychiatry, 71, pp.109~120 (2010)
41. Owen RT. Ramelteon, "profile of a new sleep-promoting medication", Drugs Today(Barc), 42, pp.255~263 (2006)
42. Romero A, "Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells", J Pineal Res, 49, pp.141~148 (2010)
43. Feng Z, "Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695transgenic mouse model of Alzheimer’s disease", J Pineal Res, 37, pp.129~136 (2004)
44. Ramos E, "Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration", Future Med Chem, 9, pp.765~780 (2017)
45. Torres-Lista V, "Neophobia, NQO1 and SIRT1 as premorbid and prodromal indicators of AD in 3xTg-AD mice", Behav Brain Res, 271, pp.140~146 (2014)
46. Reiter RJ, "Melatonin as an antioxidant : under promises but over delivers", J Pineal Res, 61, pp.253~278 (2016)
47. Rizzo V, "Determination of free and total(free plus protein-bound)melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection", J Chromatogr B Analyt Technol Biomed Life Sci, 774, pp.17~24 (2002)
48. Olakowska E, "The role of melatonin in the neurodegenerative diseases", Bratisl Lek Listy, 106, pp.171~174 (2005)
49. Srinivasan V, "Role of melatonin in neurodegenerative diseases", Neurotox Res, 7, pp.293~318 (2005)
50. Lahiri DK, "Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases", Ann N Y Acad Sci, 1056, pp.430~449 (2005)
51. Wongprayoon P, "Melatonin as a mitochondrial protector in neurodegenerative diseases", Cell Mol Life Sci, 74, pp.3999~4014 (2017)
52. Song J, "The role of melatonin in the onset and progression of type 3 diabetes", Mol Brain, 10, pp.35~ (2017)
53. Wu YH, "The human pineal gland and melatonin in aging and Alzheimer’s disease", J Pineal Res, 38, pp.145~152 (2005)
54. Lin CH, "Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease : a randomized, doubleblind, placebo-controlled trial", Biol Psychiatry, 75, pp.678~685 (2014)

관련 논문AI추천